Risultati della ricerca - Matthias Pinter

Raffina i risultati
  1. 1
    Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

    Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy di Matthias Pinter, Rakesh K. Jain

    Pubblicazione 2017
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Review article: systemic treatment of hepatocellular carcinoma

    Review article: systemic treatment of hepatocellular carcinoma di Matthias Pinter, Markus Peck‐Radosavljevic

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups di Matthias Pinter, Bernhard Scheiner, Markus Peck‐Radosavljevic

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events

    Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events di Matthias Pinter, Wilhelmus J. Kwanten, Rakesh K. Jain

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

    The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma di Matthias Pinter, Rakesh K. Jain, Dan G. Duda

    Pubblicazione 2020
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Cancer and liver cirrhosis: implications on prognosis and management

    Cancer and liver cirrhosis: implications on prognosis and management di Matthias Pinter, Michael Trauner, Markus Peck‐Radosavljevic, Wolfgang Sieghart

    Pubblicazione 2016
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy

    NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy di Matthias Pinter, David J. Pinato, Pierluigi Ramadori, Mathias Heikenwälder

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study

    The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study di Matthias Pinter, Wolfgang Sieghart, Thomas Reiberger, Nataliya Rohr‐Udilova, Arnulf Ferlitsch, Markus Peck‐Radosavljevic

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

    Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis di Matthias Pinter, Wolfgang Sieghart, Ivo Graziadei, Wolfgang Vogel, A Maieron, Robert Königsberg, Adalbert Weißmann, Gabriela Kornek, Christina Plank, Markus Peck‐Radosavljevic

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

    Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers di Vera Himmelsbach, Matthias Pinter, Bernhard Scheiner, Marino Venerito, Friedrich Sinner, Carolin Zimpel, Jens U. Marquardt, Jörg Trojan, Oliver Waidmann, Fabian Finkelmeier

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

    Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol di Thomas Reiberger, Gregor Ulbrich, Arnulf Ferlitsch, B.A. Payer, Philipp Schwabl, Matthias Pinter, Birgit Heinisch, Michael Trauner, Ludwig Kramer, Markus Peck‐Radosavljevic

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality

    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality di Dalila Costa, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, David Bauer, Rafael Paternostro, Philipp Schwabl, Bernhard Scheiner, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient

    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient di Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Georg Semmler, Lorenz Balcar, Benedikt Hofer, Michael Schwarz, David Bauer, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Pubblicazione 2024
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade

    A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade di Ivy X. Chen, Kathleen Newcomer, Kristen E. Pauken, Vikram R. Juneja, Kamila Naxerova, M. Wu, Matthias Pinter, Debattama R. Sen, Meromit Singer, Arlene H. Sharpe, Rakesh K. Jain

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study

    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to... di Katharina Pomej, Adrian Frick, Bernhard Scheiner, Lorenz Balcar, Larissa Pajancic, Anton Klotz, Alexander Kreuter, Katharina Lampichler, Katharina Regnat, Kerstin Zinober, Michael Trauner, Dietmar Tamandl, Christoph Gasché, Matthias Pinter

    Pubblicazione 2025
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma

    Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma di Bernhard Scheiner, Martha M. Kirstein, Sabine Popp, Florian Hucke, Simona Bota, Nataliya Rohr‐Udilova, Thomas Reiberger, Christian Müller, Michael Trauner, Markus Peck‐Radosavljevic, Arndt Vogel, Wolfgang Sieghart, Matthias Pinter

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death

    Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death di Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Philipp Schwabl, Albert Friedrich Stättermayer, Matthias Pinter, Ernst Eigenbauer, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension

    The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension di Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Albert Friedrich Stättermayer, Matthias Pinter, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

    Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma di Matthias Pinter, Arndt Weinmann, Marcus‐Alexander Wörns, Florian Hucke, Simona Bota, Jens U. Marquardt, Dan G. Duda, Rakesh K. Jain, Peter R. Galle, Michael Trauner, Markus Peck‐Radosavljevic, Wolfgang Sieghart

    Pubblicazione 2017
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Safety of direct oral anticoagulants in patients with advanced liver disease

    Safety of direct oral anticoagulants in patients with advanced liver disease di Georg Semmler, Katharina Pomej, David Bauer, Lorenz Balcar, Benedikt Simbrunner, Teresa Binter, Lukas Hartl, Jeannette Becker, Matthias Pinter, Peter Quehenberger, Michael Trauner, Mattias Mandorfer, Ton Lisman, Thomas Reiberger, Bernhard Scheiner

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: